Citigroup’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
Other funds holding SNDX
KCM
Citigroup's SNDX Position: Q3 2026 in Review
Citigroup reduced its Syndax Pharmaceuticals (SNDX) stake by 69% in Q3 2026, selling an estimated $2.72M and leaving 60,876 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3221.
Citigroup first reported a position in SNDX in Q2 2016 and has held it in 41 quarters since. The position peaked at $12.8M in Q3 2022. 237 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.
- Citigroup held 60,876 shares of Syndax Pharmaceuticals worth $1.14M as of Q3 2026.
- Citigroup sold 134,827 Syndax Pharmaceuticals shares in Q3 2026, an estimated $2.72M.
- Syndax Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3221 holding.
- Citigroup first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
- Citigroup's Syndax Pharmaceuticals position peaked at $12.8M in Q3 2022.
- 237 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.